| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2021: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2020: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2019: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
Using the iPS-Heps culture protocol developed by the University of Pittsburgh, we were able to culture a large number of human iPS-Heps cells in the livers of immunodeficient rats through cell transplantation. To recover a significant amount of proliferated iPS-Heps from within the rat liver, we generated immunodeficient rats transgenic with iCasp9 as a suicide gene, but we were unable to confirm cell death in the rat liver. Instead, we successfully produced severe immunodeficient rats with a knock-in of human SIRPA or KIT genes. By inducing the death of hepatocytes in these severe immunodeficient rats, we will establish a method to exclusively generate human iPS-Heps cells in vivo within immunodeficient rats.
|
